Key facts
- BIOCAPTIVA’s last known valuation is $13.8M (Feb 2026).
- It has raised $8.5M; the latest was Later Stage VC ($2.1M) in Feb 2026.
- Notable investors include Scottish Enterprise, Old College Capital, British Business Investments, University of Edinburgh Endowment, Archangel Investors — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for BIOCAPTIVA
- ·The full record, as it builds
Funding rounds
No funding rounds for BIOCAPTIVA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BIOCAPTIVA
Developer of sample capture and processing technologies designed to improve the quality and reliability of biomarker analysis. The company's platform offers surface binding polymer-based capture methods for circulating free DNA with enhanced stability and purity, enabling diagnostic laboratories, biotechnology companies and healthcare providers, to improve biomarker detection and analysis in clinical testing.
- Sector
- Healthcare
- HQ
- Edinburgh, United Kingdom
- Founded
- 2021
- Employees
- 10
- Website
- biocaptiva.com/
- Ownership
- Privately Held (backing)
BIOCAPTIVA doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BIOCAPTIVA shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BIOCAPTIVA in its N-PORT filings yet. We sweep new filings monthly.